One Stop Solution For In-Depth Market Research Reports
sales@sdki.us
TABLE OF CONTENTS
"1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.2.1 INCLUSIONS & EXCLUSIONS 44
1.3 MARKET SCOPE 45
FIGURE 1 IMMUNOASSAY MARKET 45
1.3.1 YEARS CONSIDERED 46
1.4 CURRENCY CONSIDERED 46
1.5 STAKEHOLDERS 46
1.6 SUMMARY OF CHANGES 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
FIGURE 2 RESEARCH DESIGN 48
2.1.1 SECONDARY DATA 49
2.1.1.1 Secondary sources 50
2.1.2 PRIMARY DATA 50
2.1.2.1 Key data from primary sources 51
2.1.2.2 Key industry insights 52
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 53
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 53
2.2 MARKET SIZE ESTIMATION 53
2.2.1 BOTTOM-UP APPROACH 54
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 54
FIGURE 6 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 55
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 55
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 56
FIGURE 8 DATA TRIANGULATION METHODOLOGY 56
2.4 MARKET SHARE ANALYSIS 57
2.5 STUDY ASSUMPTIONS 57
2.6 RISK ASSESSMENT 57
TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET 57
2.7 LIMITATIONS 58
2.7.1 METHODOLOGY-RELATED LIMITATIONS 58
2.7.2 SCOPE-RELATED LIMITATIONS 58
2.8 GROWTH RATE ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION) 59
FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION) 60
FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION) 61
FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION) 62
FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2022 VS. 2027 (USD BILLION) 63
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF IMMUNOASSAY MARKET 64
4 PREMIUM INSIGHTS 65
4.1 IMMUNOASSAY MARKET OVERVIEW 65
FIGURE 15 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS—KEY DRIVERS OF MARKET GROWTH 65
4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT & COUNTRY (2021) 66
FIGURE 16 REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021 66
4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT 67
FIGURE 17 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD 67
4.4 IMMUNOASSAY MARKET: GEOGRAPHIC MIX 68
FIGURE 18 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 68
4.5 IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS 69
FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 20 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 71
FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION) 71
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 72
5.2.1.1.1 Increasing use of immunoassays in oncology 72
TABLE 3 GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020 73
TABLE 4 GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020 73
5.2.1.1.2 Immunoassays for COVID-19 and other viral diagnostics 74
5.2.1.1.3 Immunoassays in drug detection and other diagnostic applications 74
TABLE 5 DETECTION OF DRUGS BY URINE TESTING 75
5.2.1.1.4 Growing geriatric population 75
FIGURE 22 GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 75
5.2.1.2 Advancements in systems and technologies 76
5.2.1.3 Growth in biotechnology and biopharmaceutical industries 77
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing 77
TABLE 6 RECENT WAIVERS OF MARKET PRODUCTS 78
5.2.1.5 Supportive government policies 79
5.2.1.6 Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing 79
5.2.2 RESTRAINTS 80
5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables 80
5.2.2.2 Technical hurdles of immunoassay kits 80
5.2.3 OPPORTUNITIES 81
5.2.3.1 Growth opportunities in emerging economies 81
5.2.3.2 Importance of companion diagnostics 82
TABLE 7 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED 83
5.2.3.3 Development of condition-specific biomarkers and tests 83
TABLE 8 NEW TESTS LAUNCHED BY KEY PLAYERS 84
5.2.3.4 Integration of microfluidics in immunoassays 84
TABLE 9 LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS 85
5.2.3.5 Improving immunoassay diagnostic technologies 85
5.2.4 CHALLENGES 85
5.2.4.1 Design challenges, complexities, and quality of antibodies 85
5.2.4.2 Dearth of skilled professionals 86
5.2.4.3 Unfavorable reimbursement scenario 86
5.2.4.4 Financial hurdles faced by physicians 86
5.3 REGULATORY OVERVIEW 87
5.3.1 US 87
TABLE 10 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 87
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES 88
5.3.2 CANADA 89
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 89
5.3.3 EUROPE 89
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES 89
5.3.4 JAPAN 90
5.3.4.1 Japan: Regulatory process for IVD devices 90
TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN 91
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.3.5 CHINA 91
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.3.6 INDIA 92
5.3.6.1 India: Regulatory process for IVD devices 92
5.3.7 INDONESIA 93
TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 93
5.3.8 RUSSIA 93
TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES 94
5.3.9 SAUDI ARABIA 94
TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 94
5.3.10 MEXICO 94
5.3.10.1 Mexico: Regulatory process for IVD devices 95
TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 95
5.3.11 BRAZIL 96
5.3.11.1 Brazil: Regulatory process for IVD devices 96
5.3.12 SOUTH KOREA 96
TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.3.13 MIDDLE EAST 97
5.3.14 AFRICA 97
5.4 TECHNOLOGY ANALYSIS 97
TABLE 20 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES 97
TABLE 21 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET 98
5.5 TRADE ANALYSIS 98
5.5.1 TRADE ANALYSIS FOR IMMUNOASSAYS 98
TABLE 22 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2021 (USD MILLION) 99
TABLE 23 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD MILLION) 99
5.6 PATENT ANALYSIS 100
5.7 VALUE CHAIN ANALYSIS 101
FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 101
5.8 SUPPLY CHAIN ANALYSIS 102
FIGURE 26 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 102
5.9 ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET 103
FIGURE 27 ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET 103
5.9.1 ROLE IN ECOSYSTEM 103
5.9.2 KEY PLAYERS OPERATING IN IMMUNOASSAY MARKET 104
5.10 PORTER’S FIVE FORCES ANALYSIS 105
TABLE 24 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS 105
5.10.1 DEGREE OF COMPETITION 105
5.10.2 BARGAINING POWER OF SUPPLIERS 105
5.10.3 BARGAINING POWER OF BUYERS 105
5.10.4 THREAT FROM SUBSTITUTES 105
5.10.5 THREAT FROM NEW ENTRANTS 106
5.11 KEY CONFERENCES & EVENTS IN 2022 106
TABLE 25 LIST OF CONFERENCES & EVENTS 106
5.12 PRICING ANALYSIS 107
TABLE 26 IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS 107
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 108
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 108
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 108
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 108
5.13.2 BUYING CRITERIA 109
FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS 109
TABLE 28 KEY BUYING CRITERIA, BY END USER 109
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 110
5.15 SCENARIO-BASED MARKET ASSESSMENT 111
5.15.1 IMMUNOASSAY MARKET FORECAST 111
FIGURE 30 PESSIMISTIC SCENARIO 111
FIGURE 31 OPTIMISTIC SCENARIO 111
FIGURE 32 REALISTIC SCENARIO 112
6 IMMUNOASSAY MARKET, BY PRODUCT 113
6.1 INTRODUCTION 114
TABLE 29 IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114
6.2 REAGENTS & KITS 114
TABLE 30 IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET 115
TABLE 31 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 32 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
6.2.1 ELISA REAGENTS & KITS 117
6.2.1.1 Wide usage in basic research and high-throughput screening 117
TABLE 33 ELISA REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 118
6.2.2 RAPID TEST REAGENTS & KITS 118
6.2.2.1 High demand for rapid test reagents & kits in remote areas to drive growth 118
TABLE 34 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 119
6.2.3 ELISPOT REAGENTS & KITS 119
6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive demand 119
TABLE 35 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 120
6.2.4 WESTERN BLOT REAGENTS & KITS 120
6.2.4.1 Gold standard for result confirmation promotes Western blotting reagents & kits 120
TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 121
6.2.5 OTHER REAGENTS & KITS 121
TABLE 37 OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 122
6.3 ANALYZERS 122
TABLE 38 IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET 123
TABLE 39 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 124
6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE 124
TABLE 40 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
6.3.1.1 Open-ended systems 125
6.3.1.1.1 Flexibility and wide availability make open-ended systems popular among users 125
TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 125
6.3.1.2 Closed-ended systems 126
6.3.1.2.1 High precision and automation are key features of closed-ended systems 126
TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 126
6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE 126
TABLE 43 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 126
6.3.2.1 Rental purchase 127
6.3.2.1.1 Convenience and lack of liability for end users drive preference for device rental 127
TABLE 44 RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 127
6.3.2.2 Outright purchase 128
6.3.2.2.1 Outright purchase is favored by government organizations, big companies, and CROs 128
TABLE 45 OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 128
7 IMMUNOASSAY MARKET, BY TECHNOLOGY 129
7.1 INTRODUCTION 130
TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 130
7.2 ELISA 130
TABLE 47 KEY ELISA SYSTEMS AVAILABLE IN MARKET 131
TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION) 132
7.2.1 ELISA MARKET, BY GENERATION 132
TABLE 49 IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 132
7.2.1.1 Third-generation & above 133
7.2.1.1.1 Third- & fourth-gen ELISA show high specificity and accuracy 133
TABLE 50 THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020–2027 (USD MILLION) 133
7.2.1.2 Second-generation & below 134
7.2.1.2.1 Cost-effectiveness of first- and second-generation tests supports their use 134
TABLE 51 SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020–2027 (USD MILLION) 134
7.2.2 ELISA MARKET, BY TYPE 135
TABLE 52 IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 135
7.2.2.1 CLIA 135
7.2.2.1.1 CLIA holds largest share of ELISA market, by type 135
TABLE 53 CLIA MARKET, BY REGION, 2020–2027 (USD MILLION) 136
7.2.2.2 IFA 136
7.2.2.2.1 IFA is used to diagnose antibodies against infectious pathogens 136
TABLE 54 IFA MARKET, BY REGION, 2020–2027 (USD MILLION) 137
7.2.2.3 Colorimetric immunoassays 137
7.2.2.3.1 Introduction of advanced techniques will support market growth 137
TABLE 55 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 138
7.3 RAPID TESTS 138
7.3.1 WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH 138
TABLE 56 KEY RAPID TESTS AVAILABLE IN MARKET 138
TABLE 57 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2020–2027 (USD MILLION) 139
7.4 WESTERN BLOTTING 140
7.4.1 WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH 140
TABLE 58 WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 140
TABLE 59 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2020–2027 (USD MILLION) 140
7.5 RADIOIMMUNOASSAYS 141
7.5.1 HIGH USAGE OF RIA FOR DIAGNOSIS AND DRUG TESTING TO DRIVE GROWTH 141
TABLE 60 IMMUNOASSAY MARKET FOR RADIOIMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION) 141
7.6 ELISPOT 141
7.6.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS 141
TABLE 61 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2020–2027 (USD MILLION) 142
7.7 OTHER TECHNOLOGIES 142
TABLE 62 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 143
8 IMMUNOASSAY MARKET, BY SPECIMEN 144
8.1 INTRODUCTION 145
TABLE 63 IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 145
8.2 BLOOD 145
8.2.1 HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH 145
TABLE 64 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 146
8.3 SALIVA 147
8.3.1 CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH 147
TABLE 65 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 147
8.4 URINE 148
8.4.1 USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS 148
TABLE 66 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 148
8.5 OTHER SPECIMENS 149
TABLE 67 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 149
9 IMMUNOASSAY MARKET, BY APPLICATION 150
9.1 INTRODUCTION 151
TABLE 68 IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 151
9.2 INFECTIOUS DISEASES 152
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 152
TABLE 69 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 152
9.3 ENDOCRINOLOGY 153
9.3.1 RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS 153
TABLE 70 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 153
9.4 CARDIOLOGY 154
9.4.1 HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH 154
TABLE 71 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS 154
TABLE 72 IMMUNOASSAY MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 155
9.5 AUTOIMMUNE DISORDERS 155
9.5.1 RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT—A KEY FACTOR DRIVING MARKET GROWTH 155
TABLE 73 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020–2027 (USD MILLION) 156
9.6 ALLERGY DIAGNOSTICS 156
9.6.1 GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS 156
TABLE 74 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 157
9.7 ONCOLOGY 157
9.7.1 RISING BURDEN OF CANCER—A POSITIVE INDICATOR OF MARKET GROWTH 157
TABLE 75 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 158
TABLE 76 IMMUNOASSAY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 159
9.8 BONE & MINERAL DISORDERS 159
9.8.1 HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 159
TABLE 77 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS 160
TABLE 78 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 160
9.9 TOXICOLOGY 160
9.9.1 DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY 160
TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING 161
TABLE 80 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS 161
TABLE 81 IMMUNOASSAY MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 162
9.10 BLOOD SCREENING 162
9.10.1 RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS 162
TABLE 82 IMMUNOASSAY MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 163
9.11 NEWBORN SCREENING 163
9.11.1 IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL—A MAJOR DRIVING FACTOR 163
TABLE 83 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING 164
TABLE 84 IMMUNOASSAY MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 165
9.12 OTHER APPLICATIONS 165
TABLE 85 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 166
10 IMMUNOASSAY MARKET, BY END USER 167
10.1 INTRODUCTION 168
TABLE 86 IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 168
10.2 HOSPITALS & CLINICS 168
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH 168
TABLE 87 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 169
10.3 CLINICAL LABORATORIES 170
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS 170
TABLE 88 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 171
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 171
10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY 171
TABLE 89 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION) 172
10.5 HOME CARE SETTINGS 172
10.5.1 RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH 172
TABLE 90 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2027 (USD MILLION) 173
10.6 BLOOD BANKS 173
10.6.1 RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING 173
TABLE 91 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2020–2027 (USD MILLION) 174
10.7 RESEARCH & ACADEMIC LABORATORIES 174
10.7.1 RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH 174
TABLE 92 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 175
11 IMMUNOASSAY MARKET, BY REGION 176
11.1 INTRODUCTION 177
TABLE 93 IMMUNOASSAY MARKET, BY REGION, 2020–2027 (USD MILLION) 177
11.2 NORTH AMERICA 178
FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 179
TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 180
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 180
TABLE 96 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 97 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 98 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 182
TABLE 99 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 182
TABLE 100 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 183
TABLE 101 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 102 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 184
TABLE 103 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 184
TABLE 104 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 185
11.2.1 US 185
11.2.1.1 US holds largest share in North American market 185
TABLE 105 US: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 186
TABLE 106 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 107 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 108 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 188
TABLE 109 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 188
TABLE 110 US: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 189
TABLE 111 US: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 112 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 190
TABLE 113 US: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 190
TABLE 114 US: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 191
11.2.2 CANADA 191
11.2.2.1 Initiatives undertaken by government bodies to support growth of market in Canada 191
TABLE 115 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 192
TABLE 116 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 117 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 118 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 194
TABLE 119 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 194
TABLE 120 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 195
TABLE 121 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 122 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 196
TABLE 123 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 196
TABLE 124 CANADA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 197
11.3 EUROPE 197
TABLE 125 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 198
TABLE 126 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 199
TABLE 127 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 128 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 129 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 200
TABLE 130 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 201
TABLE 131 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 201
TABLE 132 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 133 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 202
TABLE 134 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 203
TABLE 135 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 203
11.3.1 GERMANY 204
11.3.1.1 Germany holds largest share of EU immunoassay market 204
TABLE 136 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 205
TABLE 137 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 138 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 139 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 206
TABLE 140 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 207
TABLE 141 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 207
TABLE 142 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 143 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 208
TABLE 144 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 209
TABLE 145 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 209
11.3.2 ITALY 210
11.3.2.1 Growing geriatric population and increasing support for research to support market growth 210
TABLE 146 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 210
TABLE 147 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 148 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 149 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 212
TABLE 150 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 212
TABLE 151 ITALY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 213
TABLE 152 ITALY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 153 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 214
TABLE 154 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 214
TABLE 155 ITALY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 215
11.3.3 FRANCE 215
11.3.3.1 Rising use of POC testing and favorable reimbursement policies make France a lucrative market 215
TABLE 156 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 216
TABLE 157 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 158 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 159 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 217
TABLE 160 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 218
TABLE 161 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 218
TABLE 162 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 163 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 219
TABLE 164 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 220
TABLE 165 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 220
11.3.4 SPAIN 221
11.3.4.1 Increasing adoption of technologically advanced immunoassay systems makes Spain a relatively large market 221
TABLE 166 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 167 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 168 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 169 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 223
TABLE 170 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 223
TABLE 171 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 224
TABLE 172 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 173 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 225
TABLE 174 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 225
TABLE 175 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 226
11.3.5 UK 226
11.3.5.1 Government support for disease diagnostics and favorable investment scenario drive market in UK 226
TABLE 176 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 227
TABLE 177 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 178 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 179 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 229
TABLE 180 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 229
TABLE 181 UK: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 230
TABLE 182 UK: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 183 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 231
TABLE 184 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 231
TABLE 185 UK: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 232
11.3.6 RUSSIA 232
11.3.6.1 Lack of reimbursement and delays in approval may hinder market growth 232
TABLE 186 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 233
TABLE 187 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 188 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 189 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 234
TABLE 190 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 235
TABLE 191 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 235
TABLE 192 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 193 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 236
TABLE 194 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 237
TABLE 195 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 237
11.3.7 REST OF EUROPE 238
TABLE 196 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 238
TABLE 197 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 198 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 199 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 240
TABLE 200 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 240
TABLE 201 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 241
TABLE 202 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 203 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 242
TABLE 204 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 242
TABLE 205 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 243
11.4 ASIA PACIFIC 243
FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 244
TABLE 206 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 245
TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 245
TABLE 208 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 209 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 210 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 247
TABLE 211 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 247
TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 248
TABLE 213 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 249
TABLE 215 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 249
TABLE 216 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 250
11.4.1 JAPAN 250
11.4.1.1 Investments in healthcare technology and research to support growth in Japan 250
TABLE 217 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 251
TABLE 218 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 219 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 220 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 252
TABLE 221 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 253
TABLE 222 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 253
TABLE 223 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 224 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 254
TABLE 225 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 255
TABLE 226 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 255
11.4.2 CHINA 256
11.4.2.1 Opportunities for growth in China hampered by long product approval and registration processes 256
TABLE 227 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 257
TABLE 228 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 257
TABLE 229 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 230 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 258
TABLE 231 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 259
TABLE 232 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 259
TABLE 233 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 260
TABLE 234 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 260
TABLE 235 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 261
TABLE 236 CHINA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 261
11.4.3 INDIA 262
11.4.3.1 Growing medical tourism and healthcare infrastructure will drive use of immunoassays in India 262
TABLE 237 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 263
TABLE 238 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 239 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 240 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 264
TABLE 241 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 265
TABLE 242 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 265
TABLE 243 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 266
TABLE 244 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 266
TABLE 245 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 267
TABLE 246 INDIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 267"
"11.4.4 AUSTRALIA 268
11.4.4.1 Growing disease incidence and technological development drive market growth 268
TABLE 247 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 269
TABLE 248 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 269
TABLE 249 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 270
TABLE 250 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 270
TABLE 251 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 271
TABLE 252 AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 271
TABLE 253 AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 254 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 272
TABLE 255 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 273
TABLE 256 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 273
11.4.5 SOUTH KOREA 274
11.4.5.1 Rising healthcare spending and investments in research fuel market growth 274
TABLE 257 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 274
TABLE 258 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 259 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 260 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 276
TABLE 261 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 276
TABLE 262 SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 277
TABLE 263 SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 277
TABLE 264 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 278
TABLE 265 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 278
TABLE 266 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 279
11.4.6 INDONESIA 279
11.4.6.1 Indonesia has become a promising market and growth hotspot for foreign investors 279
TABLE 267 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 280
TABLE 268 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 269 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 270 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 281
TABLE 271 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 282
TABLE 272 INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 282
TABLE 273 INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 283
TABLE 274 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 283
TABLE 275 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 284
TABLE 276 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 284
11.4.7 REST OF ASIA PACIFIC 285
TABLE 277 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 286
TABLE 278 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 279 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 287
TABLE 280 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 287
TABLE 281 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 288
TABLE 282 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 288
TABLE 283 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 289
TABLE 284 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 289
TABLE 285 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 290
TABLE 286 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 291
11.5 LATIN AMERICA 291
TABLE 287 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 292
TABLE 288 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 292
TABLE 289 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 293
TABLE 290 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 293
TABLE 291 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 294
TABLE 292 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 294
TABLE 293 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 295
TABLE 294 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 295
TABLE 295 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 296
TABLE 296 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 296
TABLE 297 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 297
11.5.1 BRAZIL 297
11.5.1.1 Brazil was largest market for immunoassays in LATAM 297
TABLE 298 BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS 298
TABLE 299 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 298
TABLE 300 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 299
TABLE 301 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 299
TABLE 302 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 300
TABLE 303 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 300
TABLE 304 BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 301
TABLE 305 BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 301
TABLE 306 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 302
TABLE 307 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 302
TABLE 308 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 303
11.5.2 MEXICO 303
11.5.2.1 Growing lab consolidation to reduce number of labs in Mexico 303
TABLE 309 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 304
TABLE 310 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 304
TABLE 311 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 305
TABLE 312 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 305
TABLE 313 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 306
TABLE 314 MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 306
TABLE 315 MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 307
TABLE 316 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 307
TABLE 317 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 308
TABLE 318 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 308
11.5.3 REST OF LATIN AMERICA 309
TABLE 319 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 309
TABLE 320 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 310
TABLE 321 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 310
TABLE 322 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 311
TABLE 323 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 311
TABLE 324 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 312
TABLE 325 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 312
TABLE 326 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 313
TABLE 327 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 313
TABLE 328 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 314
11.6 MIDDLE EAST & AFRICA 314
11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH 314
TABLE 329 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 315
TABLE 330 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 315
TABLE 331 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 316
TABLE 332 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 316
TABLE 333 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 317
TABLE 334 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 317
TABLE 335 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 318
TABLE 336 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 318
TABLE 337 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 319
TABLE 338 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 320
12 COMPETITIVE LANDSCAPE 321
12.1 OVERVIEW 321
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 321
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY IMMUNOASSAY PRODUCT MANUFACTURERS 321
12.3 REVENUE ANALYSIS 322
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS 323
12.4 MARKET SHARE ANALYSIS 323
TABLE 339 IMMUNOASSAY MARKET: DEGREE OF COMPETITION 324
FIGURE 36 MARKET SHARE ANALYSIS, 2021 324
12.5 COMPANY EVALUATION MATRIX 325
12.5.1 STARS 325
12.5.2 EMERGING LEADERS 325
12.5.3 PERVASIVE PLAYERS 325
12.5.4 PARTICIPANTS 325
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT 326
12.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS) 327
12.6.1 PROGRESSIVE COMPANIES 327
12.6.2 STARTING BLOCKS 327
12.6.3 RESPONSIVE COMPANIES 327
12.6.4 DYNAMIC COMPANIES 327
FIGURE 38 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 328
12.7 COMPANY FOOTPRINT ANALYSIS 329
TABLE 340 COMPANY FOOTPRINT 329
TABLE 341 COMPANY PRODUCT FOOTPRINT 329
TABLE 342 COMPANY REGIONAL FOOTPRINT 330
12.8 COMPETITIVE BENCHMARKING 331
TABLE 343 IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES 331
12.9 COMPETITIVE SCENARIO 332
12.9.1 PRODUCT LAUNCHES & APPROVALS 332
TABLE 344 IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, 2019–2022 332
12.9.2 DEALS 333
TABLE 345 IMMUNOASSAY MARKET: DEALS, 2019–2022 333
12.9.3 OTHER DEVELOPMENTS 334
TABLE 346 IMMUNOASSAY MARKET: OTHER DEVELOPMENTS, 2019–2022 334
13 COMPANY PROFILES 335
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 MAJOR PLAYERS 335
13.1.1 ABBOTT LABORATORIES 335
TABLE 347 ABBOTT LABORATORIES: BUSINESS OVERVIEW 335
FIGURE 39 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 336
13.1.2 ROCHE DIAGNOSTICS 340
TABLE 348 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 340
FIGURE 40 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021) 341
13.1.3 SIEMENS HEALTHINEERS AG 347
TABLE 349 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 347
FIGURE 41 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 348
13.1.4 DANAHER CORPORATION 352
TABLE 350 DANAHER CORPORATION: BUSINESS OVERVIEW 352
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 353
13.1.5 THERMO FISHER SCIENTIFIC INC. 357
TABLE 351 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 357
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 358
13.1.6 PERKINELMER, INC. 362
TABLE 352 PERKINELMER, INC.: BUSINESS OVERVIEW 362
FIGURE 44 PERKINELMER, INC.: COMPANY SNAPSHOT (2021) 363
13.1.7 BECTON, DICKINSON AND COMPANY 366
TABLE 353 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 366
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 367
13.1.8 DIASORIN S.P.A. 370
TABLE 354 DIASORIN S.P.A.: BUSINESS OVERVIEW 370
FIGURE 46 DIASORIN S.P.A.: COMPANY SNAPSHOT (2021) 371
13.1.9 BIO-RAD LABORATORIES, INC. 374
TABLE 355 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 374
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 375
13.1.10 QUIDEL CORPORATION 378
TABLE 356 QUIDEL CORPORATION: BUSINESS OVERVIEW 378
FIGURE 48 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 379
13.1.11 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC 384
TABLE 357 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW 384
FIGURE 49 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021) 385
13.1.12 BIOMÉRIEUX 389
TABLE 358 BIOMÉRIEUX: BUSINESS OVERVIEW 389
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2021) 390
13.1.13 QIAGEN 394
TABLE 359 QIAGEN: BUSINESS OVERVIEW 394
FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2021) 395
13.1.14 SYSMEX CORPORATION 397
TABLE 360 SYSMEX CORPORATION: BUSINESS OVERVIEW 397
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 398
13.1.15 AGILENT TECHNOLOGIES 401
TABLE 361 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW 401
FIGURE 53 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021) 402
13.1.16 MINDRAY MEDICAL INTERNATIONAL COMPANY 404
TABLE 362 MINDRAY MEDICAL INTERNATIONAL COMPANY: BUSINESS OVERVIEW 404
13.2 OTHER PLAYERS 406
13.2.1 MERCK KGAA 406
13.2.2 MERIDIAN BIOSCIENCE 407
13.2.3 BIO-TECHNE 408
13.2.4 CELLABS 409
13.2.5 ABNOVA CORPORATION 410
13.2.6 J. MITRA & CO. 410
13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES) 411
13.2.8 CELL SCIENCES 411
13.2.9 ENZO BIOCHEM 412
13.2.10 CREATIVE DIAGNOSTICS 413
13.2.11 BOSTER BIOLOGICAL TECHNOLOGY 413
13.2.12 ELABSCIENCE 414
13.2.13 WAK-CHEMIE MEDICAL 414
13.2.14 SERA CARE 415
13.2.15 EPITOPE DIAGNOSTICS 415
13.2.16 KAMIYA BIOMEDICAL COMPANY 416
13.2.17 GYROS PROTEIN TECHNOLOGIES 416
13.2.18 TRIVITRON HEALTHCARE 417
13.2.19 INBIOS INTERNATIONAL, INC. 417
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 418
14.1 INSIGHTS FROM INDUSTRY EXPERTS 418
14.2 DISCUSSION GUIDE 419
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 426
14.4 AVAILABLE CUSTOMIZATIONS 428
14.5 RELATED REPORTS 428
14.6 AUTHOR DETAILS 430"
[Report Description]
"The global immunoassay market is valued at an estimated USD 40.2 billion in 2022 and is projected to reach USD 49.6 billion by 2027, at a CAGR of 4.3% during the forecast period. Market growth is driven by factors such as the increasing incidence of chronic and infectious diseases, advancements in systems and technologies, growth in the biotechnology and biopharmaceutical industries, supportive government policies, increasing adoption of immunoassay-based POC testing and rapid testing, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.
“The reagents & kits to register the largest share of the immunoassay market, by product”
The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the large consumption of reagents & kits for various procedures along with the rising volume of immunoassay-based tests performed worldwide.
“Rapid Tests segment to grow at a considerable rate among technology during the forecast period”
The immunoassay market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. Rapid tests are used to test donated blood for the detection of HIV, HCV, HBV, and HCG antibodies. Rapid tests are preferred as a preferred method in POC diagnosis, particularly in emergency and primary care settings.
“The blood segment accounted to grow at the fastest rate, by specimen, in 2021”
Based on specimens, the immunoassay market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens is anticipated to witness growth at the highest rate owing to increasing incidence of chronic and infectious diseases and rise in the rate of blood donations.
“Infectious diseases segment to register the highest growth rate among applications during the forecast period”
The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. The application segment of infectious diseases is anticipated to grow that the highest CAGR during the forecast period, owing to the rise in the number of products being launched for its diagnosis.
“Among the end users, the hospitals & clinics segment anticipated to grow at a significant rate during the forecast period”
The rise in the prevalence of chronic and infectious diseases has led to significant growth of the hospitals & clinics end user segment. The segment is also consider to register highest growth rate during the forecast period.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global immunoassay market is segmented into five regions - North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific region is expected to witness the highest growth in the immunoassay market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of chronic disorders along with developing healthcare infrastructure in Asian countries such as India and China.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 - 31%
• By Designation: C-level - 30%, D-level - 34%, and Others - 36%
• By Region: North America - 38%, Europe - 27%, Asia Pacific - 18%, Middle East & Africa – 11%, and Latin America – 6%
Lists of Companies Profiled in the Report:
• Abbott Laboratories (US)
• F. Hoffmann-La Roche (Switzerland)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific (US)
• Danaher Corporation (US)
• PerkinElmer (US)
• Becton, Dickinson and Company (US)
• DiaSorin S.p.A. (Italy)
• Bio- Rad Laboratories (US)
• Quidel Corporation (US)
• Ortho Clinical Diagnostics Holdings (US)
• bioMérieux (France)
• QIAGEN (Netherlands)
• Sysmex Corporation (Japan)
• Agilent Technologies (US)
• Mindray Medical International Company (China)
• Merck KGaA (Germany)
• Meridian Bioscience (US)
• Bio-Techne (US)
• Cellabs (Australia)
• Abnova Corporation (Taiwan)
• J. Mitra & Co. Pvt. Ltd. (India)
• Tosoh Corporation (Japan)
• Cell Sciences (US)
• Enzo Biochem (US)
• Creative Diagnostics (US)
• Boster Biological Technology (US)
• Elabscience (US)
• WAK-Chemie Medical (Germany)
• Sera Care (US)
• Epitope Diagnostics (US)
• Kamiya Biomedical Company (US)
• Gyros Protein Technologies (Sweden)
• Trivitron Healthcare (India)
• InBios International (US).
Research Coverage:
This report provides a detailed picture of the global immunoassay market. It aims at estimating the size and future growth potential of the market across different segments, such as product, technology, specimen, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunoassay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges."
TABLE OF CONTENTS
"1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.2.1 INCLUSIONS & EXCLUSIONS 44
1.3 MARKET SCOPE 45
FIGURE 1 IMMUNOASSAY MARKET 45
1.3.1 YEARS CONSIDERED 46
1.4 CURRENCY CONSIDERED 46
1.5 STAKEHOLDERS 46
1.6 SUMMARY OF CHANGES 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
FIGURE 2 RESEARCH DESIGN 48
2.1.1 SECONDARY DATA 49
2.1.1.1 Secondary sources 50
2.1.2 PRIMARY DATA 50
2.1.2.1 Key data from primary sources 51
2.1.2.2 Key industry insights 52
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 53
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 53
2.2 MARKET SIZE ESTIMATION 53
2.2.1 BOTTOM-UP APPROACH 54
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 54
FIGURE 6 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 55
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 55
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 56
FIGURE 8 DATA TRIANGULATION METHODOLOGY 56
2.4 MARKET SHARE ANALYSIS 57
2.5 STUDY ASSUMPTIONS 57
2.6 RISK ASSESSMENT 57
TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET 57
2.7 LIMITATIONS 58
2.7.1 METHODOLOGY-RELATED LIMITATIONS 58
2.7.2 SCOPE-RELATED LIMITATIONS 58
2.8 GROWTH RATE ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION) 59
FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION) 60
FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION) 61
FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION) 62
FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2022 VS. 2027 (USD BILLION) 63
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF IMMUNOASSAY MARKET 64
4 PREMIUM INSIGHTS 65
4.1 IMMUNOASSAY MARKET OVERVIEW 65
FIGURE 15 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS—KEY DRIVERS OF MARKET GROWTH 65
4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT & COUNTRY (2021) 66
FIGURE 16 REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021 66
4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT 67
FIGURE 17 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD 67
4.4 IMMUNOASSAY MARKET: GEOGRAPHIC MIX 68
FIGURE 18 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 68
4.5 IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS 69
FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 20 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 71
FIGURE 21 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION) 71
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 72
5.2.1.1.1 Increasing use of immunoassays in oncology 72
TABLE 3 GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020 73
TABLE 4 GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020 73
5.2.1.1.2 Immunoassays for COVID-19 and other viral diagnostics 74
5.2.1.1.3 Immunoassays in drug detection and other diagnostic applications 74
TABLE 5 DETECTION OF DRUGS BY URINE TESTING 75
5.2.1.1.4 Growing geriatric population 75
FIGURE 22 GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 75
5.2.1.2 Advancements in systems and technologies 76
5.2.1.3 Growth in biotechnology and biopharmaceutical industries 77
5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing 77
TABLE 6 RECENT WAIVERS OF MARKET PRODUCTS 78
5.2.1.5 Supportive government policies 79
5.2.1.6 Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing 79
5.2.2 RESTRAINTS 80
5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables 80
5.2.2.2 Technical hurdles of immunoassay kits 80
5.2.3 OPPORTUNITIES 81
5.2.3.1 Growth opportunities in emerging economies 81
5.2.3.2 Importance of companion diagnostics 82
TABLE 7 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED 83
5.2.3.3 Development of condition-specific biomarkers and tests 83
TABLE 8 NEW TESTS LAUNCHED BY KEY PLAYERS 84
5.2.3.4 Integration of microfluidics in immunoassays 84
TABLE 9 LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS 85
5.2.3.5 Improving immunoassay diagnostic technologies 85
5.2.4 CHALLENGES 85
5.2.4.1 Design challenges, complexities, and quality of antibodies 85
5.2.4.2 Dearth of skilled professionals 86
5.2.4.3 Unfavorable reimbursement scenario 86
5.2.4.4 Financial hurdles faced by physicians 86
5.3 REGULATORY OVERVIEW 87
5.3.1 US 87
TABLE 10 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 87
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES 88
5.3.2 CANADA 89
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 89
5.3.3 EUROPE 89
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES 89
5.3.4 JAPAN 90
5.3.4.1 Japan: Regulatory process for IVD devices 90
TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN 91
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.3.5 CHINA 91
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.3.6 INDIA 92
5.3.6.1 India: Regulatory process for IVD devices 92
5.3.7 INDONESIA 93
TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 93
5.3.8 RUSSIA 93
TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES 94
5.3.9 SAUDI ARABIA 94
TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 94
5.3.10 MEXICO 94
5.3.10.1 Mexico: Regulatory process for IVD devices 95
TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 95
5.3.11 BRAZIL 96
5.3.11.1 Brazil: Regulatory process for IVD devices 96
5.3.12 SOUTH KOREA 96
TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.3.13 MIDDLE EAST 97
5.3.14 AFRICA 97
5.4 TECHNOLOGY ANALYSIS 97
TABLE 20 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES 97
TABLE 21 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET 98
5.5 TRADE ANALYSIS 98
5.5.1 TRADE ANALYSIS FOR IMMUNOASSAYS 98
TABLE 22 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2021 (USD MILLION) 99
TABLE 23 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD MILLION) 99
5.6 PATENT ANALYSIS 100
5.7 VALUE CHAIN ANALYSIS 101
FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 101
5.8 SUPPLY CHAIN ANALYSIS 102
FIGURE 26 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 102
5.9 ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET 103
FIGURE 27 ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET 103
5.9.1 ROLE IN ECOSYSTEM 103
5.9.2 KEY PLAYERS OPERATING IN IMMUNOASSAY MARKET 104
5.10 PORTER’S FIVE FORCES ANALYSIS 105
TABLE 24 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS 105
5.10.1 DEGREE OF COMPETITION 105
5.10.2 BARGAINING POWER OF SUPPLIERS 105
5.10.3 BARGAINING POWER OF BUYERS 105
5.10.4 THREAT FROM SUBSTITUTES 105
5.10.5 THREAT FROM NEW ENTRANTS 106
5.11 KEY CONFERENCES & EVENTS IN 2022 106
TABLE 25 LIST OF CONFERENCES & EVENTS 106
5.12 PRICING ANALYSIS 107
TABLE 26 IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS 107
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 108
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 108
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 108
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 108
5.13.2 BUYING CRITERIA 109
FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS 109
TABLE 28 KEY BUYING CRITERIA, BY END USER 109
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 110
5.15 SCENARIO-BASED MARKET ASSESSMENT 111
5.15.1 IMMUNOASSAY MARKET FORECAST 111
FIGURE 30 PESSIMISTIC SCENARIO 111
FIGURE 31 OPTIMISTIC SCENARIO 111
FIGURE 32 REALISTIC SCENARIO 112
6 IMMUNOASSAY MARKET, BY PRODUCT 113
6.1 INTRODUCTION 114
TABLE 29 IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 114
6.2 REAGENTS & KITS 114
TABLE 30 IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET 115
TABLE 31 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 32 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
6.2.1 ELISA REAGENTS & KITS 117
6.2.1.1 Wide usage in basic research and high-throughput screening 117
TABLE 33 ELISA REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 118
6.2.2 RAPID TEST REAGENTS & KITS 118
6.2.2.1 High demand for rapid test reagents & kits in remote areas to drive growth 118
TABLE 34 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 119
6.2.3 ELISPOT REAGENTS & KITS 119
6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive demand 119
TABLE 35 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 120
6.2.4 WESTERN BLOT REAGENTS & KITS 120
6.2.4.1 Gold standard for result confirmation promotes Western blotting reagents & kits 120
TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 121
6.2.5 OTHER REAGENTS & KITS 121
TABLE 37 OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 122
6.3 ANALYZERS 122
TABLE 38 IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET 123
TABLE 39 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 124
6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE 124
TABLE 40 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
6.3.1.1 Open-ended systems 125
6.3.1.1.1 Flexibility and wide availability make open-ended systems popular among users 125
TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 125
6.3.1.2 Closed-ended systems 126
6.3.1.2.1 High precision and automation are key features of closed-ended systems 126
TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION) 126
6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE 126
TABLE 43 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 126
6.3.2.1 Rental purchase 127
6.3.2.1.1 Convenience and lack of liability for end users drive preference for device rental 127
TABLE 44 RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 127
6.3.2.2 Outright purchase 128
6.3.2.2.1 Outright purchase is favored by government organizations, big companies, and CROs 128
TABLE 45 OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION) 128
7 IMMUNOASSAY MARKET, BY TECHNOLOGY 129
7.1 INTRODUCTION 130
TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 130
7.2 ELISA 130
TABLE 47 KEY ELISA SYSTEMS AVAILABLE IN MARKET 131
TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION) 132
7.2.1 ELISA MARKET, BY GENERATION 132
TABLE 49 IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 132
7.2.1.1 Third-generation & above 133
7.2.1.1.1 Third- & fourth-gen ELISA show high specificity and accuracy 133
TABLE 50 THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020–2027 (USD MILLION) 133
7.2.1.2 Second-generation & below 134
7.2.1.2.1 Cost-effectiveness of first- and second-generation tests supports their use 134
TABLE 51 SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020–2027 (USD MILLION) 134
7.2.2 ELISA MARKET, BY TYPE 135
TABLE 52 IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 135
7.2.2.1 CLIA 135
7.2.2.1.1 CLIA holds largest share of ELISA market, by type 135
TABLE 53 CLIA MARKET, BY REGION, 2020–2027 (USD MILLION) 136
7.2.2.2 IFA 136
7.2.2.2.1 IFA is used to diagnose antibodies against infectious pathogens 136
TABLE 54 IFA MARKET, BY REGION, 2020–2027 (USD MILLION) 137
7.2.2.3 Colorimetric immunoassays 137
7.2.2.3.1 Introduction of advanced techniques will support market growth 137
TABLE 55 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 138
7.3 RAPID TESTS 138
7.3.1 WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH 138
TABLE 56 KEY RAPID TESTS AVAILABLE IN MARKET 138
TABLE 57 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2020–2027 (USD MILLION) 139
7.4 WESTERN BLOTTING 140
7.4.1 WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH 140
TABLE 58 WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 140
TABLE 59 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2020–2027 (USD MILLION) 140
7.5 RADIOIMMUNOASSAYS 141
7.5.1 HIGH USAGE OF RIA FOR DIAGNOSIS AND DRUG TESTING TO DRIVE GROWTH 141
TABLE 60 IMMUNOASSAY MARKET FOR RADIOIMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION) 141
7.6 ELISPOT 141
7.6.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS 141
TABLE 61 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2020–2027 (USD MILLION) 142
7.7 OTHER TECHNOLOGIES 142
TABLE 62 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 143
8 IMMUNOASSAY MARKET, BY SPECIMEN 144
8.1 INTRODUCTION 145
TABLE 63 IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 145
8.2 BLOOD 145
8.2.1 HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH 145
TABLE 64 IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 146
8.3 SALIVA 147
8.3.1 CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH 147
TABLE 65 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 147
8.4 URINE 148
8.4.1 USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS 148
TABLE 66 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 148
8.5 OTHER SPECIMENS 149
TABLE 67 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2020–2027 (USD MILLION) 149
9 IMMUNOASSAY MARKET, BY APPLICATION 150
9.1 INTRODUCTION 151
TABLE 68 IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 151
9.2 INFECTIOUS DISEASES 152
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 152
TABLE 69 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 152
9.3 ENDOCRINOLOGY 153
9.3.1 RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS 153
TABLE 70 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 153
9.4 CARDIOLOGY 154
9.4.1 HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH 154
TABLE 71 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS 154
TABLE 72 IMMUNOASSAY MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 155
9.5 AUTOIMMUNE DISORDERS 155
9.5.1 RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT—A KEY FACTOR DRIVING MARKET GROWTH 155
TABLE 73 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020–2027 (USD MILLION) 156
9.6 ALLERGY DIAGNOSTICS 156
9.6.1 GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS 156
TABLE 74 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 157
9.7 ONCOLOGY 157
9.7.1 RISING BURDEN OF CANCER—A POSITIVE INDICATOR OF MARKET GROWTH 157
TABLE 75 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 158
TABLE 76 IMMUNOASSAY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 159
9.8 BONE & MINERAL DISORDERS 159
9.8.1 HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 159
TABLE 77 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS 160
TABLE 78 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 160
9.9 TOXICOLOGY 160
9.9.1 DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY 160
TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING 161
TABLE 80 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS 161
TABLE 81 IMMUNOASSAY MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 162
9.10 BLOOD SCREENING 162
9.10.1 RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS 162
TABLE 82 IMMUNOASSAY MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 163
9.11 NEWBORN SCREENING 163
9.11.1 IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL—A MAJOR DRIVING FACTOR 163
TABLE 83 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING 164
TABLE 84 IMMUNOASSAY MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 165
9.12 OTHER APPLICATIONS 165
TABLE 85 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 166
10 IMMUNOASSAY MARKET, BY END USER 167
10.1 INTRODUCTION 168
TABLE 86 IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 168
10.2 HOSPITALS & CLINICS 168
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH 168
TABLE 87 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 169
10.3 CLINICAL LABORATORIES 170
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS 170
TABLE 88 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 171
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 171
10.4.1 GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY 171
TABLE 89 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION) 172
10.5 HOME CARE SETTINGS 172
10.5.1 RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH 172
TABLE 90 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2027 (USD MILLION) 173
10.6 BLOOD BANKS 173
10.6.1 RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING 173
TABLE 91 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2020–2027 (USD MILLION) 174
10.7 RESEARCH & ACADEMIC LABORATORIES 174
10.7.1 RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH 174
TABLE 92 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 175
11 IMMUNOASSAY MARKET, BY REGION 176
11.1 INTRODUCTION 177
TABLE 93 IMMUNOASSAY MARKET, BY REGION, 2020–2027 (USD MILLION) 177
11.2 NORTH AMERICA 178
FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 179
TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 180
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 180
TABLE 96 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 97 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 98 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 182
TABLE 99 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 182
TABLE 100 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 183
TABLE 101 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 102 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 184
TABLE 103 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 184
TABLE 104 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 185
11.2.1 US 185
11.2.1.1 US holds largest share in North American market 185
TABLE 105 US: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 186
TABLE 106 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 107 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 108 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 188
TABLE 109 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 188
TABLE 110 US: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 189
TABLE 111 US: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 112 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 190
TABLE 113 US: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 190
TABLE 114 US: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 191
11.2.2 CANADA 191
11.2.2.1 Initiatives undertaken by government bodies to support growth of market in Canada 191
TABLE 115 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 192
TABLE 116 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 117 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 118 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 194
TABLE 119 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 194
TABLE 120 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 195
TABLE 121 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 122 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 196
TABLE 123 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 196
TABLE 124 CANADA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 197
11.3 EUROPE 197
TABLE 125 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 198
TABLE 126 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 199
TABLE 127 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 128 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 129 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 200
TABLE 130 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 201
TABLE 131 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 201
TABLE 132 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 133 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 202
TABLE 134 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 203
TABLE 135 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 203
11.3.1 GERMANY 204
11.3.1.1 Germany holds largest share of EU immunoassay market 204
TABLE 136 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 205
TABLE 137 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 138 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 139 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 206
TABLE 140 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 207
TABLE 141 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 207
TABLE 142 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 143 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 208
TABLE 144 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 209
TABLE 145 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 209
11.3.2 ITALY 210
11.3.2.1 Growing geriatric population and increasing support for research to support market growth 210
TABLE 146 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 210
TABLE 147 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 148 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 149 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 212
TABLE 150 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 212
TABLE 151 ITALY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 213
TABLE 152 ITALY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 153 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 214
TABLE 154 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 214
TABLE 155 ITALY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 215
11.3.3 FRANCE 215
11.3.3.1 Rising use of POC testing and favorable reimbursement policies make France a lucrative market 215
TABLE 156 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 216
TABLE 157 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 158 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 159 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 217
TABLE 160 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 218
TABLE 161 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 218
TABLE 162 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 163 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 219
TABLE 164 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 220
TABLE 165 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 220
11.3.4 SPAIN 221
11.3.4.1 Increasing adoption of technologically advanced immunoassay systems makes Spain a relatively large market 221
TABLE 166 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 167 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 168 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 169 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 223
TABLE 170 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 223
TABLE 171 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 224
TABLE 172 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 173 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 225
TABLE 174 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 225
TABLE 175 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 226
11.3.5 UK 226
11.3.5.1 Government support for disease diagnostics and favorable investment scenario drive market in UK 226
TABLE 176 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 227
TABLE 177 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 178 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 179 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 229
TABLE 180 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 229
TABLE 181 UK: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 230
TABLE 182 UK: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 183 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 231
TABLE 184 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 231
TABLE 185 UK: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 232
11.3.6 RUSSIA 232
11.3.6.1 Lack of reimbursement and delays in approval may hinder market growth 232
TABLE 186 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 233
TABLE 187 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 188 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 189 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 234
TABLE 190 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 235
TABLE 191 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 235
TABLE 192 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 193 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 236
TABLE 194 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 237
TABLE 195 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 237
11.3.7 REST OF EUROPE 238
TABLE 196 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 238
TABLE 197 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 198 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 199 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 240
TABLE 200 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 240
TABLE 201 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 241
TABLE 202 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 203 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 242
TABLE 204 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 242
TABLE 205 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 243
11.4 ASIA PACIFIC 243
FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 244
TABLE 206 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 245
TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 245
TABLE 208 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 209 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 210 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 247
TABLE 211 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 247
TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 248
TABLE 213 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 249
TABLE 215 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 249
TABLE 216 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 250
11.4.1 JAPAN 250
11.4.1.1 Investments in healthcare technology and research to support growth in Japan 250
TABLE 217 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 251
TABLE 218 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 219 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 252
TABLE 220 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 252
TABLE 221 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 253
TABLE 222 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 253
TABLE 223 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 224 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 254
TABLE 225 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 255
TABLE 226 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 255
11.4.2 CHINA 256
11.4.2.1 Opportunities for growth in China hampered by long product approval and registration processes 256
TABLE 227 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 257
TABLE 228 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 257
TABLE 229 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 230 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 258
TABLE 231 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 259
TABLE 232 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 259
TABLE 233 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 260
TABLE 234 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 260
TABLE 235 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 261
TABLE 236 CHINA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 261
11.4.3 INDIA 262
11.4.3.1 Growing medical tourism and healthcare infrastructure will drive use of immunoassays in India 262
TABLE 237 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 263
TABLE 238 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 239 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 240 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 264
TABLE 241 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 265
TABLE 242 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 265
TABLE 243 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 266
TABLE 244 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 266
TABLE 245 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 267
TABLE 246 INDIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 267"
"11.4.4 AUSTRALIA 268
11.4.4.1 Growing disease incidence and technological development drive market growth 268
TABLE 247 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 269
TABLE 248 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 269
TABLE 249 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 270
TABLE 250 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 270
TABLE 251 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 271
TABLE 252 AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 271
TABLE 253 AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 254 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 272
TABLE 255 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 273
TABLE 256 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 273
11.4.5 SOUTH KOREA 274
11.4.5.1 Rising healthcare spending and investments in research fuel market growth 274
TABLE 257 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 274
TABLE 258 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 259 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 260 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 276
TABLE 261 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 276
TABLE 262 SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 277
TABLE 263 SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 277
TABLE 264 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 278
TABLE 265 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 278
TABLE 266 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 279
11.4.6 INDONESIA 279
11.4.6.1 Indonesia has become a promising market and growth hotspot for foreign investors 279
TABLE 267 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 280
TABLE 268 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 269 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 270 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 281
TABLE 271 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 282
TABLE 272 INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 282
TABLE 273 INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 283
TABLE 274 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 283
TABLE 275 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 284
TABLE 276 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 284
11.4.7 REST OF ASIA PACIFIC 285
TABLE 277 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 286
TABLE 278 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 279 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 287
TABLE 280 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 287
TABLE 281 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 288
TABLE 282 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 288
TABLE 283 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 289
TABLE 284 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 289
TABLE 285 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 290
TABLE 286 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 291
11.5 LATIN AMERICA 291
TABLE 287 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 292
TABLE 288 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 292
TABLE 289 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 293
TABLE 290 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 293
TABLE 291 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 294
TABLE 292 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 294
TABLE 293 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 295
TABLE 294 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 295
TABLE 295 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 296
TABLE 296 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 296
TABLE 297 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 297
11.5.1 BRAZIL 297
11.5.1.1 Brazil was largest market for immunoassays in LATAM 297
TABLE 298 BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS 298
TABLE 299 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 298
TABLE 300 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 299
TABLE 301 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 299
TABLE 302 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 300
TABLE 303 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 300
TABLE 304 BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 301
TABLE 305 BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 301
TABLE 306 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 302
TABLE 307 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 302
TABLE 308 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 303
11.5.2 MEXICO 303
11.5.2.1 Growing lab consolidation to reduce number of labs in Mexico 303
TABLE 309 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 304
TABLE 310 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 304
TABLE 311 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 305
TABLE 312 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 305
TABLE 313 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 306
TABLE 314 MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 306
TABLE 315 MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 307
TABLE 316 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 307
TABLE 317 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 308
TABLE 318 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 308
11.5.3 REST OF LATIN AMERICA 309
TABLE 319 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 309
TABLE 320 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 310
TABLE 321 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 310
TABLE 322 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 311
TABLE 323 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 311
TABLE 324 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 312
TABLE 325 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 312
TABLE 326 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 313
TABLE 327 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 313
TABLE 328 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 314
11.6 MIDDLE EAST & AFRICA 314
11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH 314
TABLE 329 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 315
TABLE 330 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION) 315
TABLE 331 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION) 316
TABLE 332 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION) 316
TABLE 333 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 317
TABLE 334 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION) 317
TABLE 335 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 318
TABLE 336 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION) 318
TABLE 337 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 319
TABLE 338 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION) 320
12 COMPETITIVE LANDSCAPE 321
12.1 OVERVIEW 321
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 321
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY IMMUNOASSAY PRODUCT MANUFACTURERS 321
12.3 REVENUE ANALYSIS 322
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS 323
12.4 MARKET SHARE ANALYSIS 323
TABLE 339 IMMUNOASSAY MARKET: DEGREE OF COMPETITION 324
FIGURE 36 MARKET SHARE ANALYSIS, 2021 324
12.5 COMPANY EVALUATION MATRIX 325
12.5.1 STARS 325
12.5.2 EMERGING LEADERS 325
12.5.3 PERVASIVE PLAYERS 325
12.5.4 PARTICIPANTS 325
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT 326
12.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS) 327
12.6.1 PROGRESSIVE COMPANIES 327
12.6.2 STARTING BLOCKS 327
12.6.3 RESPONSIVE COMPANIES 327
12.6.4 DYNAMIC COMPANIES 327
FIGURE 38 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 328
12.7 COMPANY FOOTPRINT ANALYSIS 329
TABLE 340 COMPANY FOOTPRINT 329
TABLE 341 COMPANY PRODUCT FOOTPRINT 329
TABLE 342 COMPANY REGIONAL FOOTPRINT 330
12.8 COMPETITIVE BENCHMARKING 331
TABLE 343 IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES 331
12.9 COMPETITIVE SCENARIO 332
12.9.1 PRODUCT LAUNCHES & APPROVALS 332
TABLE 344 IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, 2019–2022 332
12.9.2 DEALS 333
TABLE 345 IMMUNOASSAY MARKET: DEALS, 2019–2022 333
12.9.3 OTHER DEVELOPMENTS 334
TABLE 346 IMMUNOASSAY MARKET: OTHER DEVELOPMENTS, 2019–2022 334
13 COMPANY PROFILES 335
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 MAJOR PLAYERS 335
13.1.1 ABBOTT LABORATORIES 335
TABLE 347 ABBOTT LABORATORIES: BUSINESS OVERVIEW 335
FIGURE 39 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 336
13.1.2 ROCHE DIAGNOSTICS 340
TABLE 348 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 340
FIGURE 40 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021) 341
13.1.3 SIEMENS HEALTHINEERS AG 347
TABLE 349 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 347
FIGURE 41 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 348
13.1.4 DANAHER CORPORATION 352
TABLE 350 DANAHER CORPORATION: BUSINESS OVERVIEW 352
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 353
13.1.5 THERMO FISHER SCIENTIFIC INC. 357
TABLE 351 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 357
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 358
13.1.6 PERKINELMER, INC. 362
TABLE 352 PERKINELMER, INC.: BUSINESS OVERVIEW 362
FIGURE 44 PERKINELMER, INC.: COMPANY SNAPSHOT (2021) 363
13.1.7 BECTON, DICKINSON AND COMPANY 366
TABLE 353 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 366
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 367
13.1.8 DIASORIN S.P.A. 370
TABLE 354 DIASORIN S.P.A.: BUSINESS OVERVIEW 370
FIGURE 46 DIASORIN S.P.A.: COMPANY SNAPSHOT (2021) 371
13.1.9 BIO-RAD LABORATORIES, INC. 374
TABLE 355 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 374
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 375
13.1.10 QUIDEL CORPORATION 378
TABLE 356 QUIDEL CORPORATION: BUSINESS OVERVIEW 378
FIGURE 48 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 379
13.1.11 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC 384
TABLE 357 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW 384
FIGURE 49 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021) 385
13.1.12 BIOMÉRIEUX 389
TABLE 358 BIOMÉRIEUX: BUSINESS OVERVIEW 389
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2021) 390
13.1.13 QIAGEN 394
TABLE 359 QIAGEN: BUSINESS OVERVIEW 394
FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2021) 395
13.1.14 SYSMEX CORPORATION 397
TABLE 360 SYSMEX CORPORATION: BUSINESS OVERVIEW 397
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 398
13.1.15 AGILENT TECHNOLOGIES 401
TABLE 361 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW 401
FIGURE 53 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021) 402
13.1.16 MINDRAY MEDICAL INTERNATIONAL COMPANY 404
TABLE 362 MINDRAY MEDICAL INTERNATIONAL COMPANY: BUSINESS OVERVIEW 404
13.2 OTHER PLAYERS 406
13.2.1 MERCK KGAA 406
13.2.2 MERIDIAN BIOSCIENCE 407
13.2.3 BIO-TECHNE 408
13.2.4 CELLABS 409
13.2.5 ABNOVA CORPORATION 410
13.2.6 J. MITRA & CO. 410
13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES) 411
13.2.8 CELL SCIENCES 411
13.2.9 ENZO BIOCHEM 412
13.2.10 CREATIVE DIAGNOSTICS 413
13.2.11 BOSTER BIOLOGICAL TECHNOLOGY 413
13.2.12 ELABSCIENCE 414
13.2.13 WAK-CHEMIE MEDICAL 414
13.2.14 SERA CARE 415
13.2.15 EPITOPE DIAGNOSTICS 415
13.2.16 KAMIYA BIOMEDICAL COMPANY 416
13.2.17 GYROS PROTEIN TECHNOLOGIES 416
13.2.18 TRIVITRON HEALTHCARE 417
13.2.19 INBIOS INTERNATIONAL, INC. 417
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 418
14.1 INSIGHTS FROM INDUSTRY EXPERTS 418
14.2 DISCUSSION GUIDE 419
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 426
14.4 AVAILABLE CUSTOMIZATIONS 428
14.5 RELATED REPORTS 428
14.6 AUTHOR DETAILS 430"
Shibuya Data Count is a reseller offering a variety of market research reports from different industries, provided by a global team of experienced research professionals who ensure the most reliable and up-to-date research analysis reports.